Search Login Register

imatinib (Gleevec) Summary

Description: inhibits Bcr-Abl protein-tyrosine kinase; structure in first source

Also Known As: Gleevec; Glivec; imatinib mesylate; STI571; CGP 57148 Show All >>

Networked: 6703 relevant articles (1018 outcomes, 972 trials/studies) for this Drug

Key Diseases for which imatinib is Relevant

  1. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) : 405 outcomes 309 studies in 2864 results
  2. Neoplasms (Cancer) : 143 outcomes 175 studies in 1395 results
  3. Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) : 107 outcomes 108 studies in 1008 results
  4. Philadelphia Chromosome : 75 outcomes 75 studies in 507 results
  5. Leukemia : 74 outcomes 61 studies in 518 results
Show All >>

Drugs Related to imatinib

  1. imatinib (Gleevec)
  2. Protein-Tyrosine Kinases (Tyrosine Kinase)
  3. Phosphotransferases (Kinase)
  4. dasatinib (BMS 354825)
  5. 4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
  6. sunitinib (Sutent)
  7. Bcr-Abl tyrosine kinase
  8. Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
  9. Interferon-alpha (Interferon Alfa)
  10. Interferons
Show All >>

Therapies Related to imatinib

  1. Drug Therapy (Chemotherapy)
  2. Stem Cell Transplantation
  3. Aftercare (After-Treatment)
  4. Hematopoietic Stem Cell Transplantation
  5. Transplants (Transplant)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.